Suppr超能文献

含胶体银成分或银盐的非处方药品。美国卫生与公众服务部(HHS)、公共卫生服务部(PHS)、食品药品监督管理局(FDA)。最终规定。

Over-the-counter drug products containing colloidal silver ingredients or silver salts. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule.

出版信息

Fed Regist. 1999 Aug 17;64(158):44653-8.

Abstract

The Food and Drug Administration (FDA) is issuing a final rule establishing that all over-the-counter (OTC) drug products containing colloidal silver ingredients or silver salts for internal or external use are not generally recognized as safe and effective and are misbranded. FDA is issuing this final rule because many OTC drug products containing colloidal silver ingredients or silver salts are being marketed for numerous serious disease conditions and FDA is not aware of any substantial scientific evidence that supports the use of OTC colloidal silver ingredients or silver salts for these disease conditions.

摘要

美国食品药品监督管理局(FDA)正在发布一项最终规定,确定所有含有用于内服或外用的胶体银成分或银盐的非处方(OTC)药品通常不被认为是安全有效的,并且属于标签错误。FDA发布这项最终规定是因为许多含有胶体银成分或银盐的非处方药品正在针对多种严重疾病状况进行销售,而FDA并不知晓有任何实质性科学证据支持将非处方胶体银成分或银盐用于这些疾病状况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验